Windtree Therapeutics, Inc. - WINT STOCK NEWS

Windtree Therapeutics (NasdaqCM: WINT) announced that CEO Craig Fraser will present a corporate overview and hold virtual 1x1 meetings at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The presentation will be available on demand starting September 12 at 7:00 am ET. Windtree focuses on late-stage interventions for acute cardiovascular disorders, particularly developing the first-in-class treatment, istaroxime, for acute heart failure. The company also has a portfolio that includes rostafuroxin for genetically targeted hypertensive patients.

Windtree Therapeutics (NasdaqCM: WINT) has entered a global licensing agreement with Lee’s Pharmaceutical and Zhaoke Pharmaceutical for the development of its KL4 surfactant and AEROSURF® treatments for respiratory distress syndrome in preterm infants. The agreement could yield up to $78.9 million in milestones and low double-digit royalties. Lee’s and Zhaoke will cover all development costs, relieving Windtree of ongoing expenses related to the KL4 platform, thereby enhancing its financial position for core programs, particularly istaroxime for acute heart failure.

Windtree Therapeutics (NasdaqCM: WINT) reported its Q2 2022 financial results, highlighting a significant operating loss reduction to $17.5 million from $45.4 million in Q2 2021. The company achieved notable success with its Phase 2 SEISMiC study of istaroxime, demonstrating improved systolic blood pressure and cardiac function in early cardiogenic shock patients. The SEISMiC study's results have drawn positive industry interest, prompting the company to begin Phase 3 study preparations and explore licensing discussions for strategic partnerships. Windtree expects its cash runway to support operations into Q1 2023.

Windtree Therapeutics (NasdaqCM: WINT) announced positive clinical results for istaroxime in treating early cardiogenic shock, supporting a new development program. With a market potential of $1.25 billion, there is a strong demand for innovative therapies in this area. Following the promising Phase 2 SEISMiC study results, the company is engaged in discussions for partnerships and licensing opportunities to enhance shareholder value. Windtree aims to optimize resources and reduce costs while advancing istaroxime's development, focusing on creating a faster, cost-effective pathway.

Windtree Therapeutics (WINT) announced positive results from its Phase 2 study of istaroxime for early cardiogenic shock, presented at the European Society of Cardiology Heart Failure Meeting. The study met its primary endpoint, demonstrating a significant improvement in systolic blood pressure (SBP) at 6 hours compared to the control group, persisting at 24 hours. Notable secondary endpoints were also achieved, showing enhancements in cardiac function and renal maintenance. The company plans to advance the istaroxime program, aiming for further studies and regulatory discussions.

Windtree Therapeutics, Inc. (WINT) announced a conference call on May 23, 2022, to discuss the positive topline results of its Phase 2 study of istaroxime in treating early cardiogenic shock, following a late-breaking presentation at the European Society of Cardiology Heart Failure Meeting. Management will share additional findings on blood pressure changes, cardiac function, and safety measures. Cardiogenic shock, with high mortality rates, represents a significant unmet medical need, anticipating a market value of $1.25 billion. Istaroxime shows promise as a dual mechanism therapy to enhance cardiac function.

Windtree Therapeutics, Inc. (WINT) announced positive topline results from its Phase 2 SEISMiC study of istaroxime for early cardiogenic shock, showing significant improvement in systolic blood pressure compared to controls. The results will be presented at the ESC Heart Failure Conference on May 23, 2022. For Q1 2022, the company reported an operating loss of $8.3 million and a net loss of $8.1 million ($0.29 per share), an improvement from $9.0 million in Q1 2021. Cash and cash equivalents stand at $15.5 million, providing a runway into Q1 2023.

Windtree Therapeutics announced a late-breaker presentation at the European Society of Cardiology Heart Failure Conference on May 22, 2022, detailing the efficacy of Istaroxime for pre-cardiogenic shock. The Phase 2 SEISMiC study showed that patients receiving Istaroxime significantly improved systolic blood pressure compared to controls. Cardiogenic shock, with a significant global market value of $1.25 billion, underscores the need for effective treatments. A conference call will follow the presentation to discuss additional study data.

Windtree Therapeutics announced positive results from the SEISMiC Phase 2 study of istaroxime in treating early cardiogenic shock. The trial, involving 60 patients, demonstrated significant improvements in systolic blood pressure (SBP) compared to placebo. This study is pivotal as it addresses a critical need in cardiogenic shock management, which currently lacks effective pharmacological options. The results will be further detailed at the European Society of Cardiology Heart Failure meeting scheduled for May 21-24, 2022, highlighting the potential for istaroxime as a first-in-class treatment.